Published in Cancer Weekly, June 8th, 1998
Researchers from Stanford University Medical Center, California, the Fred Hutchinson Cancer Research Center, Washington, IDEC Pharmaceuticals Corp., California, the University of Virginia, and the University of Iowa, conducted a phase II clinical trial which combined the chimeric anti-CD20 monoclonal antibody, Rituximab, and (alpha)IFN in patients with CD20-positive LG/F NHL.
Results were presented at the 34th Annual Meeting of the American Society of Clinical Oncology, held May 16-19, 1998, in Los...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.